Eli Lilly (LLY) is recommended as a Strong Buy due to its attractive valuation and role as a diversification play for portfolios heavily invested in AI. Trading at about 24 times its 2027 earnings estimates, the stock is seen as premium but not overpriced. Significant institutional ownership supports its status as a core healthcare holding. The analyst remains confident in Eli Lilly's long-term growth potential and ability to outperform the S&P 500 despite recent modest gains relative to the benchmark.
Eli Lilly's reputation as a strong buy aligns with its steady performance on Pluang, where the stock trades at USD 1,162.80 as of Oct 07, 2026 17:11 WIB, showing a modest 0.46% gain in one day. The stock's market cap stands at $1.03 trillion, reflecting its significant presence in the healthcare sector. Despite a 55% sell order activity on Pluang, the typical hold time of 93 days suggests investor confidence in its medium-term prospects.
Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...
Eli Lilly's stock is predicted to rise nearly 19% over the next year, driven by rapid growth in its oncology, immunology, and neuroscience drug portfolios, which grew 121% year-over-year last quarter. While known for weight loss drugs like Mounjaro a...
Eli Lilly presented new data at the 2026 Fall Clinical Dermatology Conference highlighting EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, showing durable disease control with less frequent dosing and reduced topical treatment. ...
The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is ...
